N. Zealand To Cover Merck Integrase Inhibitor Against HIV/AIDS
This article was originally published in PharmAsia News
Executive Summary
New Zealand's drug-funding agency has decided to cover Merck's Isentress (raltegravir), an integrase inhibitor for treating HIV/AIDS